A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
evaluate the effect of administration of fluvoxamine, a CYP1A2 inhibitor, after 2-cycles of ASA404, on the pharmacokinetics of ASA404
approximately 2 months
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CASA404A2113
NCT01299415
August 2009
Name | Location |
---|---|
Cancer Therapy & Research Center | San Antonio, Texas 78229 |
Univ. of Indiana School of Medicine/Simon Cancer Center | Indianapolis, Indiana 46202 |
Masonic Cancer Center/ Clinical Trials Office | Minneapolis, Minnesota 55455 |
Washington University School of Medicine/Siteman Cancer Center | St. Louis, Missouri 63110 |